Navigation Links
Fleming Pharmaceuticals Now Ready to Step Up Production of Nuclear Radiation Safeguard, ThyroShield®
Date:4/21/2011

ST. LOUIS, April 21, 2011 /PRNewswire/ -- Fleming Pharmaceuticals, maker of ThyroShield®– the only FDA approved liquid potassium iodide product indicated for thyroid protection in radiation emergencies – announced today that it has implemented the changes necessary to ramp up production to meet increased domestic and international demand.  

ThyroShield is an over-the-counter iodide solution which, when taken orally, saturates the thyroid gland so radioactive iodine cannot be absorbed. ThyroShield is especially effective for babies and children, who are most at risk during radiation exposure.

"The March 11 incident at Japan's Fukushima Daiichi power plant has increased awareness of the need for preparedness in the event of a major nuclear emergency," stated Phill Dritsas, president of Fleming Pharmaceuticals. "Based on the number of inquiries we have received in the past month from governments, hospitals and others around the world, it is clear to us that we need to do everything within our power here at Fleming to help meet the need for global and domestic relief. We've responded by taking steps to ensure that we can significantly increase production of ThyroShield."  

Working closely with the FDA, Fleming Pharmaceuticals has qualified a new potassium iodide (KI) supplier to ensure a steady supply of quality raw materials to manufacture ThyroShield. The company has also established new agreements with vendors to shorten lead times needed to complete orders for ThyroShield package components such as bottles, caps and droppers. Finally, Fleming Pharmaceuticals has completed a thorough audit to identify production line logistics that can be immediately implemented to fulfill any significant new orders for ThyroShield.

"ThyroShield was developed under the Orphan Drug Act – a federal law designed to encourage the development of pharmaceuticals that have limited commercial potential," Dritsas said. "It has always been made-to-order, rather than produced in mass quantities like other, more common over-the-counter medications. With the production changes we've implemented over the past six weeks, we are confident that we can now fulfill increase in demand for the product."

For more information, visit www.flemingpharma.com or www.thyroshield.com.


'/>"/>
SOURCE Fleming Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Media Statement on Nuclear Crisis in Japan: Fleming Pharmaceuticals Stepping Up Production of Nuclear Antidote
2. Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
3. Hanmi Pharmaceuticals to Acquire the Rights for a Promising Phase II Anti-cancer Src Kinase/Pretubulin Dual Inhibitor from Kinex Pharmaceuticals, in Selected Asian Territories
4. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
5. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
7. Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
8. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
9. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
10. Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award
11. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
(Date:8/7/2017)... DUBLIN , Aug. 7, 2017  Endo International ... has reached agreements to resolve virtually all known U.S. ... in discussions to resolve the known remaining U.S. claims ... installment payments beginning in the fourth quarter of 2017 ... part of its second quarter 2017 results, the Company ...
(Date:8/2/2017)... , Aug. 2, 2017 Fenita ... Who as a Pinnacle Lifetime Professional in the ... Account Manager at Turing Pharmaceuticals, AG. Her skills ... and relationship building.                ... than 25 years of experience as a highly ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... Arizona ... hospitals nationally that earned the designation of High Performing Hospitals by U.S. News ... performing indicates a hospital was significantly better than the national average in a ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... Golden Bridge Awards® - for Risk Management Solution Innovations and Security Solution for ... online platform released in 2017 and its DHS SAFETY Act-designated enterprise security assessment ...
(Date:8/22/2017)... ... August 22, 2017 , ... The ... health is as simple as eating healthy foods. But this well-known piece of ... making insulin, or breaking apart carbohydrates—depends not only on properties of the food ...
(Date:8/22/2017)... ... August 22, 2017 , ... Nurses at Apple Rehab Watch ... Cove, recently received training and certification in Closed Pulse Irrigation™ (CPI) for ... five-star rating from the Centers for Medicare and Medicaid Services, to have a CPI ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert ... the creation of published author, Julianne Hale, a consultant for the Intelligence Community. ... counter-terrorism expert focusing on the Near East region. Julianne has written hundreds ...
Breaking Medicine News(10 mins):